Brokerages Set Integra LifeSciences Holdings Corporation (NASDAQ:IART) Price Target at $18.63

Integra LifeSciences Holdings Corporation (NASDAQ:IART - Get Free Report) has been assigned a consensus rating of "Reduce" from the nine ratings firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, three have assigned a hold recommendation and two have issued a buy recommendation on the company. The average 12 month target price among analysts that have issued ratings on the stock in the last year is $18.63.

A number of brokerages have weighed in on IART. JMP Securities reduced their target price on Integra LifeSciences from $35.00 to $25.00 and set a "market outperform" rating on the stock in a report on Friday, May 9th. Wells Fargo & Company cut their price objective on Integra LifeSciences from $25.00 to $13.00 and set an "equal weight" rating on the stock in a report on Tuesday, May 6th. JPMorgan Chase & Co. cut their price objective on Integra LifeSciences from $24.00 to $12.00 and set an "underweight" rating on the stock in a report on Tuesday, May 6th. Truist Financial cut their price objective on Integra LifeSciences from $26.00 to $19.00 and set a "hold" rating on the stock in a report on Friday, April 11th. Finally, Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating in a report on Monday, March 31st.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quadrant Capital Group LLC raised its position in shares of Integra LifeSciences by 5,960.9% in the 4th quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company's stock worth $32,000 after acquiring an additional 1,371 shares in the last quarter. Sterling Capital Management LLC raised its stake in Integra LifeSciences by 821.7% during the 4th quarter. Sterling Capital Management LLC now owns 2,166 shares of the life sciences company's stock worth $49,000 after buying an additional 1,931 shares during the period. Covestor Ltd raised its stake in Integra LifeSciences by 61.8% during the 4th quarter. Covestor Ltd now owns 5,423 shares of the life sciences company's stock worth $123,000 after buying an additional 2,071 shares during the period. MassMutual Private Wealth & Trust FSB raised its stake in Integra LifeSciences by 6,017.6% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 10,094 shares of the life sciences company's stock worth $124,000 after buying an additional 9,929 shares during the period. Finally, CWM LLC raised its stake in Integra LifeSciences by 413.8% during the 1st quarter. CWM LLC now owns 6,664 shares of the life sciences company's stock worth $147,000 after buying an additional 5,367 shares during the period. 84.78% of the stock is owned by institutional investors.

Integra LifeSciences Stock Performance

Shares of NASDAQ IART traded down $0.58 during trading hours on Wednesday, reaching $12.59. 692,979 shares of the stock were exchanged, compared to its average volume of 971,324. The firm has a market capitalization of $978.37 million, a price-to-earnings ratio of -33.13, a P/E/G ratio of 0.70 and a beta of 1.15. The company has a debt-to-equity ratio of 0.81, a quick ratio of 0.72 and a current ratio of 1.21. Integra LifeSciences has a 52 week low of $11.06 and a 52 week high of $32.66. The stock's fifty day simple moving average is $12.80 and its 200 day simple moving average is $18.68.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing analysts' consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The company had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same quarter last year, the business earned $0.55 EPS. Integra LifeSciences's revenue was up 3.7% on a year-over-year basis. Sell-side analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.